Biote (NASDAQ: BTMD) is a healthcare company specializing in bioidentical hormone replacement therapy and hormone optimization services. The company operates a network of clinics and offers a proprietary telemedicine platform to deliver personalized treatment plans for hormone-related issues. Biote’s core services address the needs of individuals experiencing hormonal imbalances, including menopause, andropause and thyroid dysfunction, with a focus on restoring wellness and improving quality of life through clinically guided protocols.
In addition to in-person consultations, Biote provides at-home testing kits and access to lab services that enable patients to monitor hormone levels regularly. The company’s treatment model centers on the use of bioidentical hormone pellets, which are custom-dosed and implanted in a minimally invasive procedure. Supplementing its hormone therapy offerings, Biote has developed a line of nutraceutical products designed to support metabolic health, bone density and overall vitality.
Founded in 2014 and headquartered in St. Petersburg, Florida, Biote has expanded its footprint across the United States, serving patients in more than 40 states through a combination of brick-and-mortar clinics and virtual care channels. The company has grown through strategic partnerships with independent healthcare practitioners and franchise operators, fostering a networked approach to training providers in its proprietary protocols. Over time, Biote has refined its digital platform to enhance patient engagement and outcomes tracking, positioning telehealth as a key driver of future growth.
Biote’s executive leadership team brings together expertise in endocrinology, telemedicine and healthcare operations. Chief Executive Officer Jorge Challe, M.D., leads company strategy and new market expansion, while Chief Financial Officer Lisa Reynolds oversees corporate finance and investor relations. Biote continues to invest in research and development, aiming to broaden its treatment portfolio and deepen its presence in the rapidly evolving field of hormone optimization.
AI Generated. May Contain Errors.
Free BTMD Stock Alerts